"Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment," Lilly spokeswoman Molly McCully said in an emailed statement. "Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study."Lilly shares were down about 3% at $150.
Eli Lilly coronavirus antibody trial paused for potential safety concern
By REUTERS
11/05/2024 01:08 PM
By REUTERS
11/05/2024 12:33 PM
By REUTERS
11/05/2024 12:31 PM
By REUTERS
11/05/2024 12:22 PM
By AVI ASHKENAZI
11/05/2024 11:34 AM
By REUTERS
11/05/2024 11:15 AM
By REUTERS
11/05/2024 10:54 AM
By REUTERS
11/05/2024 10:14 AM
By REUTERS
11/05/2024 01:17 AM